{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 7:', 'Supplemental Dose When Plasmapheresis/Plasma Exchange is Administered as Rescue Therapy on', 'Nonscheduled Dosing Visits', 'Body Weight', 'Volume (mL)', 'Previous', 'Next Applicable', 'Used for Most', 'Ravulizumab', 'Diluent', 'Ravulizumab or', 'Supplemental', 'Study Period', 'Recent', 'Dose', 'Placebo Scheduled', '(0.9%', 'Dosing Day', 'Ravulizumab', 'Placebo', 'Total', 'Scheduled', '(mg)', 'sodium', 'Dosing Visit', 'Range', 'Dose (kg\u00b9', 'chloride)', 'Ravulizumab Group', 'Randomized-', 'Loading dose', 'Days 2 to 14', '> 40 to < 60', '1200', '120', '0', '120', '240', 'Controlled', '(Day 1)', '> 60 to < 100', '1500', '150', '0', '150', '300', '> 100', '1500', '150', '0', '150', '300', 'Maintenance dose', 'Days 16 to 70,', '40 to < 60', '1500', '150', '0', '150', '300', '(Days 15, 71, 127)', 'Days 72 to 126,', '> 60 to < 100', '1800', '180', '0', '180', '360', 'Days 128 to 182', '100', '1800', '180', '0', '180', '360', 'Open-Label', 'Blinded dose\u00b2', 'Days 184 to 196', '40 to < 60', '600', '60', '60', '120', '240', 'Extension', '(Day 183)', '> 60 to < 100', '600', '60', '90', '150', '300', '100', '600', '60', '90', '150', '300', 'Open-label', 'On intervals', '> 40 to < 60', '1500', '150', '0', '150', '300', 'maintenance dose', 'between', '> 60 to < 100', '1800', '180', '0', '180', '360', '(Days 197 to 869 q8w)', 'scheduled visits', '> 100', '1800', '180', '0', '180', '360', 'Placebo Group', 'Randomized-', 'Loading dose', 'Days 2 to 14', '> 40 to < 60', '0', '0', '120', '120', '240', 'Controlled', '(Day 1)', '60 to < 100', '0', '0', '150', '150', '300', '100', '0', '0', '150', '150', '300', 'Maintenance dose', 'Days 16 to 70,', '> 40 to < 60', '0', '0', '150', '150', '300', '(Days 15, 71, 127)', 'Days 72 to 126,', '> 60 to < 100', '0', '0', '180', '180', '360', 'Days 128 to 182', '> 100', '0', '0', '180', '180', '360', 'Open-Label', 'Blinded loading dose\u00b3', 'Days 184 to 196', '> 40 to < 60', '1200', '120', '0', '120', '240', 'Extension', '(Day 183)', '60 to < 100', '1500', '150', '0', '150', '300', '> 100', '1500', '150', '0', '150', '300', 'Open-label', 'On intervals', '> 40 to < 60', '1500', '150', '0', '150', '300', 'maintenance dose', 'between', '> 60 to < 100', '1800', '180', '0', '180', '360', '(Days 197 to 869,', 'scheduled visits', '> 100', '1800', '180', '0', '180', '360', 'q8w)', \"1 Supplemental dose will be based on the patient's body weight used to determine the most recently administered scheduled dose.\", '2 Blinded dose on Day 183 (Week 26) for patients who were randomized to the ravulizumab group and are entering into the Open-Label Extension Period.', '3 Blinded loading dose on Day 183 (Week 26) for patients who were randomized to the placebo group and are entering into the Open-Label Extension Period.', 'Page 47 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 8:', 'Supplemental Dose When Intravenous Immunoglobulin is Administered as Rescue Therapy on Nonscheduled', 'Dosing Visits', 'Body Weight', 'Volume (mL)', 'Previous', 'Next Applicable', 'Used for Most', 'Ravulizumab', 'Diluent', 'Ravulizumab or', 'Supplemental', 'Study Period', 'Recent', 'Dose', 'Placebo Scheduled', '(0.9%', 'Dosing Day', 'Ravulizumab', 'Placebo', 'Total', 'Scheduled Dose', '(mg)', 'sodium', 'Dosing Visit', 'Range', '(kg\u00b9', 'chloride)', 'Ravulizumab Group', 'Loading dose', 'Days 2 to 14', '40 to < 60', '600', '60', '0', '60', '120', '(Day 1)', '60 to < 100', '600', '60', '0', '60', '120', 'Randomized-', '100', '600', '60', '0', '60', '120', 'Controlled', 'Maintenance dose', 'Days 16 to 70,', '40 to < 60', '600', '60', '0', '60', '120', '(Days 15, 71, 127)', 'Days 72 to 126,', '> 60 to < 100', '600', '60', '0', '60', '120', 'Days 128 to 182', '100', '600', '60', '0', '60', '120', 'Blinded dose\u00b2', 'Days 184 to 196', '40 to < 60', '600', '60', '0', '60', '120', '> 60 to < 100', '600', '60', '0', '60', '120', '(Day 183)', '> 100', '600', '60', '0', '60', '120', 'Open-Label', 'Open-label', 'On intervals', '40 to < 60', '600', '60', '0', '60', '120', 'Extension', 'maintenance dose', 'between', '> 60 to < 100', '600', '60', '0', '60', '120', '(Days 197 to 869', 'scheduled visits', '> 100', '600', '60', '0', '60', '120', 'q8w)', 'Placebo Group', 'Loading dose', 'Days 2 to 14', '40 to < 60', '0', '0', '60', '60', '120', '(Day 1)', '60 to < 100', '0', '0', '60', '60', '120', 'Randomized-', '> 100', '0', '0', '60', '60', '120', 'Controlled', 'Maintenance dose', 'Days 16 to 70,', '40 to < 60', '0', '0', '60', '60', '120', '(Days 15, 71, 127)', 'Days 72 to 126,', '60 to < 100', '0', '0', '60', '60', '120', 'Days 128 to 182', '> 100', '0', '0', '60', '60', '120', 'Days 184 to 196', '40 to < 60', '600', '60', '0', '60', '120', 'Blinded loading dose\u00b3', '> 60 to < 100', '600', '60', '0', '60', '120', '(Day 183)', '> 100', '600', '60', '0', '60', '120', 'Open-Label', 'Extension', 'Open-label', 'On intervals', '40 to < 60', '600', '60', '0', '60', '120', 'maintenance dose', 'between', '> 60 to < 100', '600', '60', '0', '60', '120', '(Days 197 to 869,', 'scheduled visits', '> 100', '600', '60', '0', '60', '120', 'q8w)', \"1 Supplemental dose will be based on the patient's body weight used to determine the most recently administered scheduled dose.\", '2 Blinded dose on Day 183 (Week 26) for patients who were randomized to the ravulizumab group and are entering into the Open-Label Extension Period.', '3 Blinded loading dose on Day 183 (Week 26) for patients who were randomized to the placebo group and are entering into the Open-Label', 'Extension', 'Period.', 'Page 48 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}